RECRUITINGOBSERVATIONAL
Blinatumomab Consolidation in Real World
Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
About This Trial
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Who May Be Eligible (Plain English)
Who May Qualify:
- 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give willing to sign a consent form (or retrospective data for deceased patients
Who Should NOT Join This Trial:
- N/A
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* 1\) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients
Exclusion Criteria:
* N/A
Locations (1)
Medical College of Wisconsin
Milwaukee, Wisconsin, United States